The NALA (NCT01808573) phase III clinical trial provided clinical evidence that neratinib was more effective than lapatinib when combined with capecitabine in HER2+ breast cancer patients, extending progression-free survival (PFS) (12 month PFS = 29 % versus 15 %). Here, ERBB2 is linked to breast carcinoma.